-
1 Comment
KYORIN Holdings, Inc is currently in a long term downtrend where the price is trading 7.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
KYORIN Holdings, Inc's total revenue sank by 10.2% to $27B since the same quarter in the previous year.
Its net income has dropped by 32.6% to $2B since the same quarter in the previous year.
Based on the above factors, KYORIN Holdings, Inc gets an overall score of 1/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | JP3247090008 |
| Market Cap | 86B |
|---|---|
| PE Ratio | 17.8 |
| Target Price | 1300 |
| Beta | -0.05 |
| Dividend Yield | 4.3% |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4569.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
